Inventor
LAVEDAN CHRISTIAN
US26 patents
⚠️ This page may combine multiple inventors who share the name “LAVEDAN CHRISTIAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
VANDA PHARMACEUTICALS INC
16 patentsUS11078289B2Aug 3, 2021
Cancer treatment
VANDA PHARMACEUTICALS INC5 citations84
US10653665B2May 19, 2020
Method of treatment
VANDA PHARMACEUTICALS INC8 citations84
US10265282B2Apr 23, 2019
Cancer treatment
VANDA PHARMACEUTICALS INC6 citations84
US10179119B2Jan 15, 2019
Method of treatment
VANDA PHARMACEUTICALS INC10 citations84
US9458507B1Oct 4, 2016
Antipsychotic treatment based on SNP genotype
VANDA PHARMACEUTICALS INC7 citations83
US11737993B2Aug 29, 2023
Multiple myeloma treatment
VANDA PHARMACEUTICALS INC3 citations73
US11667718B2Jun 6, 2023
Cancer treatment
VANDA PHARMACEUTICALS INC3 citations73
US11266622B2Mar 8, 2022
Method of treatment
VANDA PHARMACEUTICALS INC3 citations73
US10563261B2Feb 18, 2020
Method of predicting a predisposition to QT prolongation
VANDA PHARMACEUTICALS INC2 citations72
US12590162B2Mar 31, 2026
Cancer treatment
VANDA PHARMACEUTICALS INC0 citations62
US11458154B2Oct 4, 2022
Treatment of CYR61- and VEGF-mediated conditions
VANDA PHARMACEUTICALS INC0 citations62
US10570452B2Feb 25, 2020
Method of predicting a predisposition to QT prolongation
VANDA PHARMACEUTICALS INC1 citations62
US10563260B2Feb 18, 2020
Method of predicting a predisposition to QT prolongation
VANDA PHARMACEUTICALS INC1 citations62
US9408839B2Aug 9, 2016
Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
VANDA PHARMACEUTICALS INC1 citations62
US9243295B2Jan 26, 2016
Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
VANDA PHARMACEUTICALS INC1 citations62
US10570453B2Feb 25, 2020
Method of predicting a predisposition to QT prolongation
VANDA PHARMACEUTICALS INC1 citations59
LAVEDAN CHRISTIAN
9 patentsUS9328387B2May 3, 2016
Antipsychotic treatment based on SNP genotype
LAVEDAN CHRISTIAN16 citations92
US9080214B2Jul 14, 2015
Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
LAVEDAN CHRISTIAN8 citations83
US9074255B2Jul 7, 2015
Method of predicting a predisposition to QT prolongation
LAVEDAN CHRISTIAN6 citations82
US9074256B2Jul 7, 2015
Method of predicting a predisposition to QT prolongation
LAVEDAN CHRISTIAN6 citations82
US9072742B2Jul 7, 2015
Method of predicting a predisposition to QT prolongation
LAVEDAN CHRISTIAN6 citations82
US8652776B2Feb 18, 2014
Prediction of QT prolongation based on SNP genotype
LAVEDAN CHRISTIAN12 citations80
US9074254B2Jul 7, 2015
Method of predicting a predisposition to QT prolongation
LAVEDAN CHRISTIAN6 citations69
US9057104B2Jun 16, 2015
Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
LAVEDAN CHRISTIAN1 citations61
US11060144B2Jul 13, 2021
Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
LAVEDAN CHRISTIAN1 citations59